Tumor-infiltrating CD8 T cells were found to frequently express the inhibitory receptor
NKG2A, particularly in immune-reactive environments and after therapeutic cancer …

Therapeutic vaccination with human papillomavirus type 16 synthetic long peptides (HPV16-
SLPs) results in T cell–mediated regression of HPV16-induced premalignant lesions but …

The accumulation of tumor-specific CD4+ and CD8+ effector T cells is key to an effective
antitumor response. Locally, CD4+ T cells promote the recruitment and effector function of …

Oropharyngeal squamous cell carcinoma (OPSCC) develops as a consequence of several
mutations in the tumor suppressor pathways or after a progressive infection with high risk …

Immune therapy is a promising field within oncology but has been unsuccessful in ovarian
cancer (OC). Still, there is rationale and evidence supporting immune therapy in OC. We …

Background Chemoradiotherapy (CRT) remains one of the most common cancer treatment
modalities, and recent data suggest that CRT is maximally effective when there is generation …

Purpose: The tumor immune microenvironment determines clinical outcome. Whether the
original tissue in which a primary tumor develops influences this microenvironment is not …

The surface inhibitory receptor NKG2A forms heterodimers with the invariant CD94 chain
and is expressed on a subset of activated CD8 T cells. As antibodies to block NKG2A are …

Background Cross-presentation of exogenous antigens in HLA-class I molecules by
professional antigen presenting cells (APCs) is crucial for CD8+ T cell function. Recent …

Background The composition of the tumor immune microenvironment (TIME) associated with
good prognosis generally also predicts the success of immunotherapy, and both entail the …